The 3P Laboratory (Pharmacokinetics (PK), Pharmacodynamics (PD) and Pharmacogenetics (PG)) was established by the UWCCC more than 25 years ago to support the translational and clinical research activities of our members. The mission of the 3P Laboratory is to advance cancer research by providing expertise;leadership;and bioanalytical assay development, validation and performance in support of the clinical, translational and laboratory research endeavors of UWCCC investigators. The 3P Lab provides UWCCC members with sample acquisition, processing, storage and shipping services for all PK/PD/PG clinical studies. It provides analysis of samples for PK/PD/PG studies in support of multiple NCI grants as well as research conducted by individual UWCCC investigators. In addition, the 3P Lab provides services for investigators in the preclinical setting to support new drug development. Services include generation of tumor xenografts for testing of investigational compounds, as well as evaluating plasma and intra-tumor drug levels in animal models. This service includes development and performance of original assays for new agents;assays to monitor endogenous biochemicals;and genotyping and mutation assays. Finally, the 3P Lab offers access to their bioanalytical instrumentation to trained UWCCC investigators.

Public Health Relevance

The 3P Laboratory (Pharmacokinetics, Pharmacodynamics and Pharmacogenetics) provides analytical support for biospecimens obtained in the clinical trials conducted at the University of Wisconsin Carbone Cancer Center.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Wisconsin Madison
United States
Zip Code
Litzelman, Kristin; Keller, Abiola O; Tevaarwerk, Amye et al. (2018) Adequacy of Depression Treatment in Spouses of Cancer Survivors: Findings From a Nationally Representative US Survey. J Gen Intern Med 33:869-876
Chute, Colleen; Yang, Xinhai; Meyer, Kristy et al. (2018) Syndecan-1 induction in lung microenvironment supports the establishment of breast tumor metastases. Breast Cancer Res 20:66
Farnoodian, Mitra; Sorenson, Christine M; Sheibani, Nader (2018) Negative Regulators of Angiogenesis, Ocular Vascular Homeostasis, and Pathogenesis and Treatment of Exudative AMD. J Ophthalmic Vis Res 13:470-486
Nayak, Amruta P; Kapur, Arvinder; Barroilhet, Lisa et al. (2018) Oxidative Phosphorylation: A Target for Novel Therapeutic Strategies Against Ovarian Cancer. Cancers (Basel) 10:
Gangnon, Ronald E; Stout, Natasha K; Alagoz, Oguzhan et al. (2018) Contribution of Breast Cancer to Overall Mortality for US Women. Med Decis Making 38:24S-31S
Gurel, Zafer; Sheibani, Nader (2018) O-Linked ?-N-acetylglucosamine (O-GlcNAc) modification: a new pathway to decode pathogenesis of diabetic retinopathy. Clin Sci (Lond) 132:185-198
Li, Chao; Yu, Jiaquan; Paine, Paxton et al. (2018) Double-exclusive liquid repellency (double-ELR): an enabling technology for rare phenotype analysis. Lab Chip 18:2710-2719
Braun, Rudolf K; Chetty, Chandramu; Balasubramaniam, Vivek et al. (2018) Intraperitoneal injection of MSC-derived exosomes prevent experimental bronchopulmonary dysplasia. Biochem Biophys Res Commun 503:2653-2658
Schumacher, Jessica R; Neuman, Heather B; Chang, George J et al. (2018) A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment (AFT-01). Ann Surg Oncol 25:2587-2595
Turk, Anita A; Wisinski, Kari B (2018) PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Cancer 124:2498-2506

Showing the most recent 10 out of 1528 publications